US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

AVIR Atea Pharmaceuticals Inc

3.45

0.10 (2.99%)

02 Ene 2025 - Cerrado

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/17/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

03/04/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for JPM Partners LLC

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Atea Pharmaceuticals (NASDAQ:AVIR)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025

Haga Click aquí para más Gráficas Atea Pharmaceuticals.

Atea Pharmaceuticals (NASDAQ:AVIR)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025

Haga Click aquí para más Gráficas Atea Pharmaceuticals.

Noticias sobre Atea Pharmaceuticals Inc AVIR

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
Lunes 16 de Diciembre 2024 (3 semanas hace) • GlobeNewswire Inc.

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
Miércoles 4 de Diciembre 2024 (4 semanas hace) • GlobeNewswire Inc.

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
Martes 26 de Noviembre 2024 (1 mes hace) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Martes 19 de Noviembre 2024 (1 mes hace) • Edgar (US Regulatory)

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Viernes 15 de Noviembre 2024 (2 meses hace) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jueves 7 de Noviembre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 8-K - Current report
Jueves 7 de Noviembre 2024 (2 meses hace) • Edgar (US Regulatory)

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Jueves 7 de Noviembre 2024 (2 meses hace) • GlobeNewswire Inc.

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
Jueves 31 de Octubre 2024 (2 meses hace) • GlobeNewswire Inc.

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
Miércoles 30 de Octubre 2024 (2 meses hace) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Jueves 19 de Septiembre 2024 (3 meses hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Miércoles 18 de Septiembre 2024 (3 meses hace) • Edgar (US Regulatory)

Más de Atea Pharmaceuticals Inc Artículos de Noticias

Super Micro Computer

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones